Login
Natera, Inc. logo

Natera, Inc.

natera.com

What Do They Do?

Sells genetic diagnostic tests for cancer patients, people seeking prenatal or hereditary screening, and transplant recipients.

How Do They Make Money?

Most money comes from genetic tests for patients, clinics and insurers. Natera generally bills when test results are delivered; laboratory partners may pay a fixed amount per test or a share of their collections.

revenue
SegmentShareRevenue
Product
Sold outright

100%
FY2022: 97%
Licensing and other
Usage-based
0.5%
FY2022: 2.8%

Who Are Their Customers?

Customers include independent and reference laboratories, medical centers, physician practices, research laboratories and pharmaceutical companies. Tests are sold through Natera’s direct sales force and laboratory partners; some partners bill clinics, patients and insurers themselves.

Do Revenues Turn Into Profits?

Not on paper. It lost $208.2M in FY2025, but brought in more cash than it spent: $109.1M of free cash flow.

Operating income, FY2025
−13% of revenue
▼ −39% (Loss) vs FY2024 (−$222.3M, −13%)
Net income, FY2025
−9% of revenue
▼ −9% (Loss) vs FY2024 (−$190.4M, −11%)
Free cash flow, FY2025
5% of revenue
▲ +58% vs FY2024 ($69.2M, 4%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +34%
vs $592.2M in Q3 FY2025
Net income
▲ +32% (Loss)
vs −$87.5M in Q3 FY2025
Product revenues share of revenue vs 99.7% in Q3 FY2025
  • Aug 6, 2026 Natera raised its 2026 revenue guidance. The updated annual revenue outlook is $2.85 billion to $2.91 billion.

Growing. Revenue grew 3.7x in 4 years, from $625.5M in FY2021 to $2.3B in FY2025, about 39% a year.

Broader oncology focus The older report described oncology as an area where the company was proving its technology and commercializing a personalized blood test. The latest report describes a broader oncology offering, including tests for monitoring cancer and treatment response, genomic profiling and hereditary cancer screening.

Revenue over time
Product Licensing and other
$2.5B$1.3B$0

Who Do They Compete With?

Competes with BGI, BillionToOne, Fulgent Genetics, Illumina, Labcorp, Myriad Genetics, Quest Diagnostics, Revvity, Caris Life Sciences, Exact Sciences, Guardant Health, Personalis, Tempus Labs, and CareDx

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support